U.S. patent application number 09/758988 was filed with the patent office on 2001-08-09 for microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream.
Invention is credited to Ottoboni, Thomas B., Short, Robert E., Yamamoto, Ronald K..
Application Number | 20010012522 09/758988 |
Document ID | / |
Family ID | 25299908 |
Filed Date | 2001-08-09 |
United States Patent
Application |
20010012522 |
Kind Code |
A1 |
Ottoboni, Thomas B. ; et
al. |
August 9, 2001 |
Microparticles useful as ultrasonic contrast agents and for
delivery of drugs into the bloodstream
Abstract
Microparticles are provided comprising a shell of an outer layer
of a biologically compatible material and an inner layer of
biodegradable polymer. The core of the microparticles contain a
gas, liquid or solid for use in drug delivery or as a contrast
agent for ultrasonic contrast imaging. The microparticles are
capable of passing through the capillary systems of a subject.
Inventors: |
Ottoboni, Thomas B.;
(Belmont, CA) ; Short, Robert E.; (Los Gatos,
CA) ; Yamamoto, Ronald K.; (San Francisco,
CA) |
Correspondence
Address: |
REGINALD J. SUYAT
Fish & Richardson P.C.
Suite 100
2200 Sand Hill Road
Menlo Park
CA
94025
US
|
Family ID: |
25299908 |
Appl. No.: |
09/758988 |
Filed: |
January 11, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09758988 |
Jan 11, 2001 |
|
|
|
09070474 |
Apr 30, 1998 |
|
|
|
6193951 |
|
|
|
|
09758988 |
Jan 11, 2001 |
|
|
|
08847153 |
Apr 30, 1997 |
|
|
|
Current U.S.
Class: |
424/501 |
Current CPC
Class: |
A61K 49/223 20130101;
A61K 49/225 20130101; A61K 47/6925 20170801; A61K 41/0028
20130101 |
Class at
Publication: |
424/501 |
International
Class: |
A61K 009/50 |
Claims
What is claimed is:
1. A microparticle composition containing microparticles having
diameters within the range of about 1 to 10 microns, an outer layer
of a biologically compatible material and an inner layer comprising
a biodegradable polymer.
2. A composition according to claim 1, wherein at least a majority
of said microparticles have diameters within said range.
3. A composition according to claim 1, wherein said microparticles
have hollow cores.
4. A composition according to claim 1, wherein said microparticles
comprise solid cores.
5. A composition according to claim 1, wherein said biologically
compatible material is blood compatible.
6. A composition according to claim 1, wherein said outer layer
comprises a chemically cross-linked amphiphilic biopolymer.
7. A composition according to claim 3, wherein said cores contain a
gas.
8. A composition according to claim 3, wherein said cores contain a
liquid.
9. A composition according to claim 1 or 7, wherein said
microparticles contain a drug.
10. A composition comprising gas-filled microparticles of a size
capable of passing the capillary circulation system of the body,
wherein said microparticles are mechanically adjusted to resonate
at a predetermined resonant frequency.
11. A composition according to claim 10, wherein said
microparticles are selected to resonate at said frequency by
particle size selection.
12. A composition according to claim 11, wherein the particle
diameter is within the range of about 1 to 10 microns.
13. A composition according to claim 10, wherein said resonant
frequency is .gtoreq.2 MHz.
14. A composition according to claim 13, wherein said frequency is
.gtoreq.5 MHz.
15. A composition according to claim 10, wherein the mechanical
adjustment is made by selection of wall thickness.
16. A composition according to claim 10, wherein the mechanical
adjustment is made by selection of wall material for said
microparticles.
17. A composition according to claim 10, wherein the mechanical
adjustment is made by selection of the extent of cross-linking of
the wall material of said microparticles.
18. A composition according to claim 10, wherein the mechanical
adjustment is made by the adjustment of the internal pressure
within said microparticles.
19. A composition according to claim 10, wherein said resonant
frequency is in the range of the transmitted frequencies of a
diagnostic body imaging system.
20. A composition according to claim 10, wherein said resonant
frequency is a harmonic of a diagnostic body imaging system.
21. A composition according to claim 10, wherein the microparticles
are mechanically adjusted to remain stable when exposed to a
threshold diagnostic imaging level of power of ultrasound
irradiation, and are rupturable when exposed to an increase in said
power.
22. A composition according to claim 10, wherein the microparticles
are mechanically adjusted to remain stable when exposed to a
threshold diagnostic imaging level of power of ultrasound
irradiation, and are rupturable when exposed to frequencies near
the resonant frequency of the microparticles.
23. A composition according to claim 21 or 22, wherein said
microparticles contain a drug.
24. A composition according to claim 21 or 22, wherein said
microparticles contain blood soluble or insoluble gases.
25. A composition comprising gas-filled microparticles of a size
capable of passing the capillary circulation system of the body and
comprising surface targeting moieties for binding to selected
tissues.
26. A composition comprising gas-filled microparticles of a size
capable of passing the capillary circulation system of the body and
comprising surface conjugated hydrophilic polymers.
27. A composition according to claim 26 wherein said hydrophilic
polymers comprise polyethylene glycol.
28. A composition according to claim 26 comprising polyethylene
glycol, polypropylene glycol, their derivatives, and combinations
thereof.
29. A composition according to claim 25 comprising a
chemically-charged outer surface.
30. A composition according to claim 28 wherein said outer surface
is PEGylated.
31. A composition according to claim 29 wherein said outer surface
is succinylated.
32. A composition according to claim 25, wherein said targeting
moieties are selected from the group consisting of antibodies, cell
receptors, lectins, selecting, integrins, receptor targets,
receptor analogues, and active fragments thereof.
33. A composition according to claim 1, wherein said biologically
compatible material comprise a protein.
34. A composition according to claim 1, wherein said biologically
compatible material comprises collagen, gelatin, albumin, globulin,
or glycosaminoglycan.
35. A composition according to claim 1, wherein said biologically
compatible material comprises albumin.
36. A composition according to claim 1, wherein said biologically
compatible material comprises a biopolymer.
37. A composition according to claim 1, wherein said biologically
compatible material comprises gelatin.
38. A composition according to claim 1, wherein said biodegradable
polymer comprises a synthetic polymer.
39. A composition according to claim 38, wherein said polymer
comprises polycaprolactone.
40. A composition according to claim 38, wherein said polymer
comprises polylactide, polyglycolide, or copolymers thereof.
41. A composition according to claim 38, wherein said polymer
comprises copolymers of caprolactone with lactic or glycolic
acid.
42. A composition according to claim 1, wherein said inner layer is
porous.
43. A process for forming multilayer microparticles which are
suspendable in a medium suitable for injection, comprising the
steps: a. forming a mixture of a first aqueous dispersion of a
biologically compatible material and mixing with a second solution
of a biodegradable polymer wherein said second solution comprises a
relatively volatile water-immiscible solvent and a relatively
non-volatile water-immiscible non-solvent for said polymer; b.
emulsifying said mixture from step (a) to form microdroplets having
an interior containing said polymer solution and an outer layer
comprising said biologically compatible material; c. removing said
relatively volatile solvent from said microparticles to form an
inner layer of said polymer on said biopolymer; d. drying said
microparticles to remove said non-solvent and residual water.
44. A process according to claim 43, wherein said step (c) said
volatile solvent is removed by evaporation.
45. A process according to claim 43, wherein said step (c) said
volatile is removed by dilution.
46. A process according to claim 43 further comprising the step of
cross-linking said outer layer.
47. A process according to claim 43, wherein said step (d) is by
freeze drying.
48. A process according to claim 43 further comprising the step of
loading said microparticles after drying with a gas other than
air.
49. A process according to claim 43 further comprising the step of
microparticle size selection.
50. A method of generating an image for echogenic inspection
comprising the steps of: a. introducing into a subject a
composition of gas-filled microparticles capable of passing the
capillary circulation system of said subject wherein said
microparticles have an outer layer comprising a biologically
compatible material and an inner layer comprising a biodegradable
polymer; b. subjecting said subject to suitable ultrasonic
radiation; c. detecting ultrasonic radiation reflected,
transmitted, resonated and/or frequency and/or amplitude modulated
by said microparticles in said subject.
51. A method according to claim 50, wherein at least a majority of
said microparticles have diameters within the range of about 1 to
10 microns.
52. A method of delivering a pharmaceutically active agent to a
subject comprising the steps of introducing into the subject a
composition comprising microparticles capable of passing the
capillary circulation of said subject, having an outer layer
comprising a biologically compatible material, an inner layer
comprising a biodegradable polymer and containing said
pharmaceutically active agent.
53. A method according to claim 52, wherein at least a majority of
said microparticles has a diameter within the range of about 1 to
10 microns.
54. A method according to claim 52 further comprising the step of
applying localized ultrasound energy to the target tissue or organ
to release the pharmaceutically active agent at the specifically
desired site.
55. A method according to claim 54 where the target organ is the
heart.
56. A method according to claim 55 where the target tissue is a
tumor.
Description
BACKGROUND OF THE INVENTION
[0001] This is a continuation-in-part of Ser. No. 08/847,153, filed
Apr. 30, 1997, incorporated by reference herein in its
entirety.
[0002] Hollow microparticles, sometimes called microbubbles or
microspheres, are efficient for back scattering ultrasound energy.
Thus, small microbubbles injected into the bloodstream, can enhance
ultrasonic echographic imaging to aid the visualization of internal
structures, such as the heart and blood vessels. The ultrasound
contrast is achieved when acoustic impedance between two materials
at an interface is different. Thus, the greater the difference of
acoustic impedance between the materials, the greater the intensity
of an ultrasound echo from that interface. Since there is a large
difference between the acoustic impedance between body tissue and
gas, gas containing microparticles circulating within tissue or
blood are strong back scatterers of the ultrasound energy. For use
in the circulatory system, microparticles should have a diameter of
less than about ten microns in order to pass through the
capillaries of the circulatory system. The lower limit of
sufficient echogenicity of a microparticle is about one to two
microns.
[0003] In cardiology, microparticles are useful for intravenous
injection, thereby providing ultrasound contrast in the right
chambers of the heart, enhancing identification of cardiac
structures, valve functions and detection of intracardiac shunts.
However in order to visualize the left chambers of the heart, the
microparticles must first pass through the pulmonary circulation
system. Such particles must be small enough to pass through the
pulmonary capillaries. Otherwise they are trapped within the lungs.
They must also have sufficient structural strength to survive the
pressures within the left chambers of the heart.
[0004] Microparticles also permit the definition of volumes, wall
motion, and other factors that identify diseased states within the
heart. The use of contrast agents also facilitates use of Doppler
ultrasound techniques because strong echo sources moving in the
bloodstream are far more echogenic than red blood cells, which are
the usual echo sources used in Doppler ultrasound techniques.
Contrast agents in blood may also be used to locate the presence of
blood in areas of the body or identify the absence of blood by the
lack of echogenicity in areas that should be echogenic. Examples of
such uses are the use of microparticles for assessment of perfusion
to the myocardium, and for assessment of defects in the coronary
septum by the flow of particles through the septum separating the
cardiac chambers. Another example is the use of microparticles to
identify vascular emboli such as blood clots, and abnormal growths
into the vascular chambers by the absence of the ultrasonic
contrast.
[0005] Other uses of contrast agents are to examine organ
perfusion, such as to assess the damage caused by an infarct, to
examine organs such as the liver, or to differentiate between
normal and abnormal tissues, such as tumors and cysts.
[0006] The present invention provides microparticle contrast agents
which are delivered intravenously but are capable of passing
through the pulmonary circulation system for enhanced examination
and diagnosis of both sides of the heart as well as examination of
other tissues and organs as described above.
[0007] In addition to diagnostic imaging, the microparticles
according to the present invention are also used for drug delivery
where the drug is released from the particle by diffusion from the
microparticle, by degradation of the microparticle, or by rupture
of the particle using ultrasonic energy.
SUMMARY OF THE INVENTION
[0008] The present invention provides compositions of
microparticles of which the majority of the microparticles have
diameters within the range of about one to ten microns, have an
outer layer comprising a biologically compatible material and an
inner layer comprising a biodegradable polymer. The microparticles
may have a hollow core, containing either a gas or a liquid, or a
solid core.
[0009] The outer layer may be chosen on the basis of
biocompatibility with the blood stream and tissues, whereas the
inner layer may be selected on the basis desired mechanical and
acoustic properties. The materials of both layers may be selected
to predetermine the strength of the microparticle, for example to
provide a desired resonant frequency and stability within threshold
diagnostic imaging levels of ultrasound radiation. Methods for
forming the multi-layered microparticles and the use in ultrasonic
diagnostic imaging and drug delivery are also provided. The layers
may also be chosen by their capability to contain and deliver
drugs.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIG. 1 is a graph of the time course of the reflected
ultrasound intensity in the left atrium in a test of a contrast
agent according to example 7.
[0011] FIG. 2 is a graph of the time course of the reflected
ultrasound intensity in the left atrium of the contrast agent
tested in accordance with example 8.
[0012] FIG. 3 is a graph of the volumetric size distribution of the
unfiltered microcapsules made in example 13, and the size
distribution of when the suspension is filtered.
[0013] FIG. 4 shows the resonant frequencies of two microcapsule
preparations having different wall compositions which were tested
in accordance with example 18.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] As used herein the term microparticles is intended to
include microcapsules, microspheres and microbubbles which are
hollow particles enclosing a core which may be filled with a gas or
liquid. It also includes particles in which the core may be a solid
material. It is not necessary for the microparticles to be
precisely spherical although they generally will be spherical and
described as having average diameters. If the microparticles are
not spherical, then the diameters are referred to or linked to the
diameter of a corresponding spherical microparticle having the same
mass and enclosing approximately the same volume of interior space
as a non-spherical microparticle.
[0015] The microparticles according to the present invention have a
bi-layered shell. The outer layer of the shell will be a
biologically compatible material or biomaterial since it defines
the surface which will be exposed to the blood and tissues within
the body. The inner layer of the shell will be a biodegradable
polymer, which may be a synthetic polymer, which may be tailored to
provide the desired mechanical and acoustic properties to the shell
or provide drug delivery properties. For use as ultrasound contrast
agents, the cores of the microparticles contain gas, typically air
or nitrogen. However, for drug delivery purposes the core may
either be a liquid or a different solid material from the shell
layers. To make the microparticles rupturable by a low intensity
ultrasound energy, however, they must contain a gas to allow
acoustic coupling and particle oscillation. Microparticles are
constructed herein such that the majority of those prepared in a
composition will have diameters within the range of about one to
ten microns in order to pass through the capillary system of the
body.
[0016] Since the microparticles have an outer and inner layer, the
layers can be tailored to serve different functions. The outer
shell which is exposed to the blood and tissues serves as the
biological interface between the microparticles and the body. Thus
it will be made of a biocompatible material which is typically
amphiphilic, that is, has both hydrophobic and hydrophilic
characteristics. Blood compatible materials are particularly
preferred. Such preferred materials are biological materials
including proteins such as collagen, gelatin or serum albumins or
globulins, either derived from humans or having a structure similar
to the human protein, glycosoaminoglycans such as hyaluronic acid,
heparin and chondroiten sulphate and combinations or derivatives
thereof. Synthetic biodegradable polymers, such as polyethylene
glycol, polyethylene oxide, polypropylene glycol and combinations
or derivatives may also be used. The outer layer is typically
amphiphilic, as well as having a chemistry which allows charge and
chemical modification. The versatility of the surface allows for
such modifications as altering the charge of the outer shell, such
as by selecting a type A gelatin having an isoelectric point above
physiological pH, or by using a type B gelatin having an
isoelectric point below physiological pH. The outer surfaces may
also be chemically modified to enhance biocompatibility, such as by
PEGylation, succinylation or amidation, as well as being chemically
binding to the surface targeting moiety for binding to selected
tissues. The targeting moieties may be antibodies, cell receptors,
lectins, selecting, integrins or chemical structures or analogues
of the receptor targets of such materials. The mechanical
properties of the outer layer may also be modified, such as by
cross linking, to make the microparticles suitable for passage to
the left ventricle, to provide a particular resonant frequency for
a selected harmonic of the diagnostic imaging system, or to provide
stability to a threshold diagnostic imaging level of the ultrasound
radiation.
[0017] The inner shell will be a biodegradable polymer, which may
be a synthetic polymer. An advantage of the inner shell is that it
provides additional mechanical or drug delivery properties to the
microparticle which are not provided or insufficiently provided by
the outer layer, or enhances mechanical properties not sufficiently
provided by the outer layer, without being constrained by surface
property requirements. For example, a biocompatible outer layer of
a cross-linked proteinaceous hydrogel can be physically supported
using a high modulus synthetic polymer as the inner layer. The
polymer may be selected for its modulus of elasticity and
elongation, which define the desired mechanical properties. Typical
biodegradable polymers include polycaprolactone, polylactic acid,
polylactic-polyglycolic acid co-polymers, co-polymers of lactides
and lactones, such as epsilon-caprolactone, delta-valerolactone,
polyalkylcyanoacrylates, polyamides, polyhydroxybutryrates,
polydioxanones, poly-beta-aminoketones, polyanhydrides,
poly-(ortho)esters, polyamino acids, such as polyglutamic and
polyaspartic acids or esters of polyglutamic and polyaspartic
acids. References on many biodegradable polymers are cited in
Langer. et. al. (1983) Macromol.Chem.Phys.C23, 61-125.
[0018] The inner layer permits the modification of the mechanical
properties of the shell of the microparticle which are not provided
by the outer layer alone. Moreover, the inner layer may provide a
drug carrier and/or drug delivery capacity which is not sufficient
or providable by the outer layer alone. For use as an ultrasonic
contrast agent, the inner layer will typically have thickness which
is no larger than is necessary to meet the minimum mechanical or
drug carrying/delivering properties, in order to maximize the
interior gas volume of the microparticle. The greater the gas
volume within the microparticle the better the echogenic
properties.
[0019] The combined thickness of the outer and inner layers of the
microparticle shell will depend in part on the mechanical and drug
carrying/delivering properties required of the microparticle, but
typically the total shell thickness will be in the range of 25 to
750 nm.
[0020] The microparticles may be prepared by an emulsification
process to control the sequential interfacial deposition of shell
materials. Due to the amphiphilicity of the material forming the
outer layer, stable oil/water emulsions may be prepared having an
inner phase to outer phase ratio approaching 3:1, without phase
inversion, which can be dispersable in water to form stable organic
phase droplets without the need for surfactants, viscosity
enhancers or high shear rates.
[0021] Two solutions are prepared, the first being an aqueous
solution of the outer biomaterial. The second is a solution of the
polymer which is used to form the inner layer, in a relatively
volatile water-immiscible liquid which is a solvent for the
polymer, and a relatively non-volatile water-immiscible liquid
which is a non-solvent for the polymer. The relatively volatile
water-immiscible solvent is typically a C5-C7 ester, such as
isopropyl acetate. The relatively non-volatile water-immiscible
non-solvent is typically a C6-C20 hydrocarbon such as decane,
undecane, cyclohexane, cyclooctane and the like. In the second
solution containing the polymer for the inner layer, the polymer in
water-immiscible solvents are combined so that the polymer fully
dissolves and the two solvents are miscible with agitation. The
polymer solution (organic phase) is slowly added to the biomaterial
solution (aqueous phase) to form a liquid foam. Typically about
three parts of the organic polymer solution having a concentration
of about 0.5 to 10 percent of the polymer is added to one part of
the aqueous biomaterial solution having a concentration of about 1
to 20 percent of the biomaterial. The relative concentrations of
the solutions and the ratio of organic phase to aqueous phase
utilized in this step essentially determine the size of the final
microparticle and wall thickness. After thorough mixing of the
liquid foam, it is dispersed into water and typically warmed to
about 30-35.degree. C. with mild agitation. While not intending to
be bound by a particular theory, it is believed that the
biomaterial in the foam disperses into the warm water to stabilize
an emulsion of the polymer in the organic phase encapsulated within
a biomaterial envelope. To render the biomaterial envelope water
insoluble, a cross linking agent, such as glutaraldehyde, is added
to the mixture to react with the biomaterial envelope and render it
water insoluble, stabilizing the outer shell. Other cross-linking
agents may be used, including the use of carbodiimide
cross-linkers.
[0022] Since at this point the inner core contains a solution of a
polymer, a solvent and a non-solvent with different volatilities,
as the more volatile solvent evaporates, or is diluted, the polymer
precipitates in the presence of the less volatile non-solvent. This
process forms a film of precipitate at the interface with the inner
surface of the biomaterial shell, thus forming the inner shell of
the microparticle after the more volatile solvent has been reduced
in concentration either by dilution, evaporation or the like. The
core of the microparticle then contains predominately the organic
non-solvent. The microparticles may then be isolated by
centrifugation, washed, formulated in a buffer system, if desired,
and dried. Typically, drying by lyophilization removes not only the
non-solvent liquid core but also the residual water to yield
gas-filled hollow microparticles.
[0023] It may be desirable to further modify the surface of the
microparticle, for example, in order to passivate surfaces against
macrophages or the reticuloendothelial system (RES) in the liver.
This may be accomplished, for example by chemically modifying the
surface of the microparticle to be negatively charged since
negatively charged particles appear to better evade recognition by
macrophages and the RES than positively charged particles. Also,
the hydrophilicity of the surface may be changed by attaching
hydrophilic conjugates, such as polyethylene glycol (PEGylation) or
succinic acid (succinylation) to the surface, either alone or in
conjunction with the charge modification.
[0024] The biomaterial surface may also be modified to provide
targeting characteristics for the microparticle. The surface may be
tagged by known methods with antibodies or biological receptors.
For example, if the microparticle were treated to target tumors and
were hollow, they could be used for ultrasound detection to enhance
diagnosis of the tumors. If the microparticles were filled with
drugs they could be used to target the tumors where the drug could
be preferentially released at the target site, for example, by
increasing the ultrasonic energy to rupture the particles at the
appropriate time and location.
[0025] The microparticles may also be sized or processed after
manufacture. This is an advantage over lipid-like microparticles
which may not be subjected to mechanical processing after they are
formed due to their fragility.
[0026] The final formulation of the microparticles after
preparation, but prior to use, is in the form of a lyophilized
cake. The later reconstitution of the microparticles may be
facilitated by lyophilization with bulking agents which provide a
cake having a high porosity and surface area. The bulking agents
may also increase the drying rate during lyophilization by
providing channels for the water and solvent vapor to be removed.
This also provides a higher surface area which would assist in the
later reconstitution. Typical bulking agents are sugars such as
dextrose, mannitol, sorbitol and sucrose, and polymers such as
PEG's and PVP's.
[0027] It is undesirable for the microparticles to aggregate,
either during formulation or during later reconstitution of the
lyophilized material. Aggregation may be minimized by maintaining a
pH of at least one to two pH units above or below the isoelectric
point(P.sub.i) of the biomaterial forming the outer surface. The
charge on the surface is determined by the pH of the formulation
medium. Thus, for example, if the surface of the biomaterial has a
P.sub.i of 7 and the pH of the formulation medium is below 7, the
microparticle will possess a net positive surface charge.
Alternatively, if the pH of the formulation medium is greater than
7, the microparticle would possess a negative charge. The maximum
potential for aggregation exist when the pH of the formulation
medium approaches the P.sub.i of the biomaterial used in the outer
shell. Therefore by maintaining a pH of the formulation medium at
least one to two units above or below the P.sub.i of the surface,
microparticle aggregation will be minimized. As an alternative, the
microparticles may be formulated at or near the P.sub.i with the
use of surfactants to stabilize against aggregation. In any event,
buffer systems of the final formulation to be injected into the
subject should be physiologically compatible.
[0028] The bulking agents utilized during lyophilization of the
microparticles may also be used to control the osmolality of the
final formulation for injection. An osmolality other than
physiological osmolality may be desirable during the lyophilization
to minimize aggregation. However, when formulating the
microparticles for use, the volume of liquid used to reconstitute
the microparticles must take this into account.
[0029] Other additives may be included in order to prevent
aggregation or to facilitate dispersion of the microparticles upon
formulation. Surfactants may be used in the formulation such as
poloxomers (polyethylene glycol-polypropylene glycol-polyethylene
glycol block co-polymers). Water soluble polymers also may assist
in the dispersion of the microparticles, such as medium molecular
weight polyethyleneglycols and low to medium molecular weight
polyvinylpyrolidones.
[0030] If the formulation is to contain a drug-containing core, the
microparticles may be soaked in a solution of the drug whereby the
solution diffuses into the interior. In particular, the use of
bilayered microparticles where the inner shell has a porous
characteristic allows for rapid diffusion of a drug solution into
the hollow core. The microparticles may be re-dried such as by
lyophilization to produce a gas filled, drug containing
microparticle. The combination of the drug with prefabricated
particles allows one to avoid processing which may lead to drug
degradation. To provide microparticles having a solid core
containing a drug, during formation of the microparticles, the
thickness of the inner layers may be increased to occupy more or
all of the interior volume. Then, by later soaking in the
drug-containing solution, the inner solid core will absorb the drug
and provide a solid reservoir for the drug. Alternatively, the drug
may be dissolved in the organic phase with the biopolymer during
the microparticle forming process. Evaporation of the organic
solvents causes the drug to coprecipitate with the biopolymer
inside the microparticle.
[0031] It will be realized that various modifications of the
above-described processes may be provided without departing from
the spirit and scope of the invention. For example, the wall
thickness of both the outer and inner layers may be adjusted by
varying the concentration of the components in the
microparticle-forming solutions. The mechanical properties of the
microparticles may be controlled, not only by the total wall
thickness and thicknesses of the respective layers, but also by
selection of materials used in each of the layers by their modulus
of elasticity and elongation, and degree of cross-linking of the
layers. Upon certain conditions involving rapid deposition of the
inner polymer or very low inner polymer content porosity of the
inner polymer shell is observed. The pores range from approximately
0.1 to 2 micron in diameter as observed under electron microscopy.
Mechanical properties of the layers may also be modified with
plasticizers or other additives. Adjustment of the strength of the
shell may be modified, for example, by the internal pressure within
the microparticles. Precise acoustical characteristics of the
microparticle may be achieved by control of the shell mechanical
properties, thickness, as well as narrow size distribution. The
microparticles may be ruptured by ultrasonic energy to release
gases trapped within the microparticles into the blood stream. In
particular, by appropriately adjusting the mechanical properties,
the particles may be made to remain stable to threshold diagnostic
imaging power, while being rupturable by an increase in power
and/or by being exposed to its resonant frequency. The resonant
frequency can be made to be within the range of transmitted
frequencies of diagnostic body imaging systems or can be a harmonic
of such frequencies. During the formulation process the
microparticles may be prepared to contain various gases, including
blood soluble or blood insoluble gases. It is a feature of the
invention that microparticle compositions may be made having a
resonant frequency greater or equal to 2 MHz, and typically greater
or equal to 5 MHz.
[0032] Typical diagnostic or therapeutic targets for microparticles
of the invention are the heart and tumors.
[0033] The following examples are provided by way of illustration
but are not intended to limit the invention in any way.
EXAMPLE 1
[0034] Preparation of Gelatin Polycaprolactone Microparticles
[0035] A solution of 1.0 gms gelatin (275 bl, isoelectric point of
4.89) dissolved in 20 ml deionized water was prepared at
approximately 60 C. Native pH of the solution was 5.07. Separately,
1.0 gms polycaprolactone (M.W. 50,000) and 6.75 ml cyclooctane was
dissolved in 42 ml isopropyl acetate with stirring at approximately
70 C. After cooling to 37 C, the organic mixture was then slowly
incorporated into the gelatin solution maintained at 30 C and under
moderate shear mixing using a rotary mixer. Once the organic phase
was fully incorporated, the mixing rate was increased to 2,500 rpm
for 5 minutes and then stirred at low shear for an additional 5
minutes. The resulting o-w emulsion was then added with stirring to
350 ml deionized water maintained at 30 C and containing 1.2 ml 25%
gluteraldehyde. Immediately after the addition of the emulsion, the
bath pH was adjusted to 4.7. After 30 minutes, the pH was adjusted
to 8.3. Low shear mixing was continued for approximately 21/2 hours
until the isopropyl acetate had completely volatilized. Polyoxamer
188 in the amount of 0.75 gm was then dissolved into the bath. The
resulting microparticles were retrieved by centrifugation and
washed 2 times in an aqueous solution of 0.25% polyoxamer 188.
[0036] Microscopic inspection of the microparticles revealed
spherical capsules having a thin-walled polymer shell encapsulating
a liquid organic core. Staining the slide preparation with
coomassie blue G indicated the presence of an outer protein layer
uniformly surrounding the polymer shell.
[0037] The particle size spectrum was determined using a Malvern
Micro. Median diameter was 4.78 microns with a spectrum span of
0.94.
EXAMPLE 2
[0038] Preparation of Contrast Agent Formulation
[0039] A quantity of microparticles prepared in a manner similar to
example 1 were suspended into an aqueous solution of 25 mM glycine,
0.5% pluronic f-127, 1.0% sucrose, 3.0% mannitol, and 5.0%
PEG-3400. The suspension was then lyophilized. The resulting dry
powder was reconstituted in deionized water and examined under the
microscope to reveal that the microparticles now contained a
gaseous core. Staining the preparation with commassie blue G
confirmed that the outer protein layer surrounding the capsules was
intact and had survived the lyophilization process.
[0040] Echogenicity was confirmed by insonating at both 21/2 and 5
MHz a quantity of lyophilized microparticles dispersed in 120 ml
deionized water. Measurement was taken at least 15 minutes after
dispersion of the microcapsules to insure that the back scattered
signal was due solely from the gas contained within the
microparticles. The B mode display showed a high contrast
indicating that the microparticles were gas filled.
EXAMPLE 3
[0041] Preparation of Gelatin Polylactide Microparticles
[0042] A solution of 1.2 gm gelatin (225 bloom, isoelectric point
of 5.1) dissolved in 20 ml deionized water was prepared at
approximately 50 C. Solution pH was adjusted to 6.1 using 1 M NaOH.
Separately, 0.07 gms paraffin, 4.5 ml decane, and 0.69 gms poly
DL-lactide (inherent viscosity of 0.69 dL/gm in CHCl.sub.2 @ 30 C)
was dissolved into 37 ml isopropyl acetate. The organic mixture was
then slowly incorporated into the gelatin solution which was being
maintained at 30 C under moderate shear mixing using a rotary
mixer. Once the organic phase was fully incorporated, the mixing
rate was increased to 2,000 rpm for 2 minutes and then reduced to
approximately 1,000 rpm for 4 minutes. The resulting liquid foam
was mixed into 350 ml deionized water maintained at 30 C and 1 ml
25% gluteraldehyde was then added dropwise. Rotary mixing was
continued for approximately 3 hours until the isopropyl acetate had
volatilized. The resulting microparticles were retrieved by
centrifugation and washed 2 times in an aqueous solution of 0.25%
pluronic f-127.
[0043] Microscopic inspection revealed hollow spherical
microparticles having an outer protein layer and an inner organic
liquid core.
[0044] The microparticles were lyophilized and tested in a manner
similar to example 2. The results confirmed that the microparticles
contained a gaseous core and were strongly echogenic.
EXAMPLE 4
[0045] Preparation of Gelatin Polycaprolactone Microparticles
[0046] A solution of 1.0 gm gelatin (225 bloom, isoelectric point
of 5.1) dissolved in 20 ml deionized water was prepared at
approximately 60 C. Solution pH was 4.8. Separately, 0.57 gms
polycaprolactone (M.W. 50,000) was dissolved into 1.72 ml
tetrahydrofuran. To this was added with stirring a mixture of 0.07
gms paraffin, 0.475 gm triethyl citrate, 4.5 ml cyclooctane, and 42
ml isopropyl acetate. The organic mixture was then slowly
incorporated into the gelatin solution which was maintained at 30 C
and under moderate shear mixing using a rotary mixer. Once the
organic phase was fully incorporated, the mixing rate was increased
to 4,700 rpm for 2 minutes and then reduced to 2,000 rpm for 4
minutes. The resulting liquid foam was then added with stirring to
350 ml of 30 C deionized water. To crosslink the gelatin, 1 ml of
25% glutaraldehyde was added dropwise. Mixing was continued for
approximately 3 hours until the isopropyl acetate had volatilized.
The resulting microparticles were retrieved by centrifugation and
washed 2 times in a 0.25% pluronic f-127 solution.
[0047] Microscopic inspection revealed discrete hollow spherical
polymer microparticles having an outer protein layer and an inner
organic liquid core.
[0048] The microparticles were lyophilized and tested in a manner
similar to example 2. The results confirmed that the microparticles
contained a gaseous core and were strongly echogenic.
EXAMPLE 5
[0049] Preparation of Gelatin Polycaprolactone Microparticles with
Cardodiimide Cross-Linking
[0050] A solution of 1.0 grams gelatin (225 bloom, isoelectric
point of 5.1) dissolved into 20 ml deionized water was prepared at
approximately 60 C. Solution pH was adjusted to 5.5 with 1 M NaOH.
Separately, 0.85 gms polycaprolactone (M.W. 80,000) was dissolved
in 2.5 ml tetrahydrofuran. To this was added with stirring a
mixture of 0.07 gms paraffin, 4.5 ml cyclooctane and 42 ml
isopropyl acetate. The organic mixture was then slowly incorporated
into the gelatin solution which was maintained at 30 C and under
moderate shear mixing using a rotary mixer. Once the organic phase
was fully incorporated, the mixing rate was increased to 3,500 rpm
for 6 minutes and then reduced to 3,000 rpm for 4 minutes. The
resulting liquid foam was then dispersed with low shear mixing into
350 ml of a 0.5 M NaCl solution maintained at 30 C. Gelatin
crosslinking was accomplished by the slow addition of 200 mg of
1-ethyl-3-(3-dimethylamino-propyl)carbo- diimide dissolved in 3.0
ml deionized water. Mixing was continued for approximately 3 hours
until the isopropyl acetate had volatilized. The resulting
microparticles were retrieved by centrifugation and washed 2 times
in an aqueous solution of 0.25% Pluronic f-127.
[0051] Microscopic inspection revealed discrete hollow spherical
polymer microparticles having an outer protein layer and an inner
organic liquid core.
EXAMPLE 6
[0052] Preparation of Surface PEGylated Microparticles
[0053] Microcapsules were prepared in a manner similar to example
1. After centrifugation the cream (approximately 15 ml) was
retrieved and dispersed into a solution of 65 ml deionized water,
0.50 gms methoxy-PEG-NCO (M.W. 5000), and 0.50 ml triethylamine.
After allowing the mixture to react overnight at room temperature
and with mild agitation, the capsules were retrieved by
centrifugation and washed 3 times in a neutrally buffered solution
of 0.25% Pluronic f-127.
EXAMPLE 7
[0054] Canine Study of Echogenicity
[0055] One vial of lyophilized microparticles prepared in Example 2
were reconstituted using water. A transesophageal ultrasound probe
was positioned in the esophagus of an anesthetized dog such that a
four-chamber view of the heart was obtained. The microparticle
suspension was injected into the femoral vein of the dog. The
appearance of the contrast agent was clearly noted in the
ultrasound image of the right chambers of the heart. Subsequently,
the agent was observed in the left chambers of the heart indicating
the passage through the capillary system of the lungs. The
time-course of the reflected ultrasound intensity in the left
atrium was determined by video densitometry. The agent was seen to
persist in the left chambers of the heart for approximately 6
minutes (FIG. 1).
EXAMPLE 8
[0056] Canine Study of Echogenicity using PEGylated
Microparticles
[0057] One vial of lyophilized microparticles prepared in Example 6
was reconstituted using water. A transesophageal ultrasound probe
was positioned in the esophagus of an anesthetized dog such that a
four-chamber view of the heart was obtained. The microparticle
suspension was injected into the femoral vein of the dog. The
appearance of the contrast agent was clearly noted in the
ultrasound image of the right chambers of the heart. Subsequently,
the agent was observed in the left chambers of the heart indicating
the passage through the capillary system of the lungs. The
time-course of the reflected ultrasound intensity in the left
atrium was determined by video densitometry. The agent was seen to
persist in the left chambers of the heart for approximately 16
minutes (FIG. 2) after which time no further data was
collected.
EXAMPLE 9
[0058] Preparation of Albumin Polycaprolactone Microparticles
[0059] A 6% aqueous solution was prepared from a 25% solution of
USP grade human serum albumin (Alpha Therapeutic Corp) by dilution
with deionized water. The solution was adjusted to a pH of 3.49
using 1 N HCl. Separately, 8 parts by weight polycaprolactone (M.W.
50,000) and 45 parts cyclooctane were dissolved in 300 parts
isopropyl acetate at approximately 70 C. Once dissolution was
complete, the organic solution was allowed to cool to 37 C. With
mild stirring, 42.5 gm of the prepared organic solution was slowly
incorporated into 25.0 gm of the albumin solution while the mixture
was maintained at 30 C. The resulting coarse o-w emulsion was then
circulated through a stainless steel sintered metal filter element
having a nominal pore size of 7 microns. Recirculation of the
emulsion was continued for 8 minutes. The emulsion was then added
with stirring to 350 ml deionized water maintained at 30 C and
containing 1.0 ml of 25% gluteraldehyde. During the addition, the
pH of the bath was monitored to insure that it remained between 7
and 8. Final pH was 7.1. Low shear mixing was continued for
approximately 21/2 hours until the isopropyl acetate had completely
volatilized. Poloxamer 188 in the amount of 0.75 gm was then
dissolved into the bath. The resulting microparticles were
retrieved by centrifugation and washed 2 times in an aqueous
solution of 0.25% poloxamer.
[0060] Microscopic inspection of the suspension revealed spherical
particles having a thin-walled polymer shell with an outer protein
layer and an organic liquid core. The peak diameter as, determined
by the Malvern Micro particle size analyzer, was 4.12 microns.
[0061] The suspension was then lyophilized in a manner similar to
that described in Example 2. The resulting dry cake was
reconstituted with deionized water and examined under the
microscope to reveal that the microparticles were spherical,
discrete, and contained a gaseous core.
EXAMPLE 10
[0062] Protein Content of Microparticles
[0063] Microparticles were prepared in accordance with example 9.
After centrifugation approximately 1 ml of the microparticle
containing cream was retrieved and diluted 10 to 1 using deionized
water. From the diluted cream, 20 microliter samples were then
prepared in triplicate at 1.times., 2.times., and 4.times.dilutions
with deionized water. Protein content of the samples were
determined using a Pierce calorimetric BCA assay and a bovine serum
albumin standard. Average total protein of the diluted cream was
determined to be 0.441 mg/ml. To determine the total dry weight of
the diluted cream, 2 ml were dried in a 40 C oven until no further
weight change was observed (approximately 16 hours). The average
weight of 4 replicates was 6.45 mg/ml. The percent dry weight of
protein which can be used as a measure of the ratio of the protein
outer layer to the polymer inner layer of the microcapsule wall can
be determined with the following formula.
Average total protein/ml+dry weight/ml.times.100%
[0064] The percent dry weight of protein was calculated to be
6.8%.
EXAMPLE 11
[0065] Preparation of Albumin Polylactide Microparticles
[0066] A 6% aqueous solution was prepared from a 25% solution of
USP grade human albumin by dilution with deionized water. Ion
exchange resin (AG 501-X8, BioRad Laboratories) was then added to
the solution at a ratio of 1.5 gm resin to 1.0 gm dry weight of
albumin. After 3 hours the resin was removed by filtration and the
pH of the solution was adjusted from 4.65 to 5.5 Separately, 0.41
gm d-l lactide (0.69 dL/gm in CHCl.sub.3: at 30 C) and 5.63 gm
cyclooctane were dissolved in 37.5 gm isopropyl acetate. The
organic solution was then slowly incorporated into 25.0 gm of the
prepared albumin solution with mild stirring while the mixture was
maintained at 30 C. The resulting coarse o-w emulsion was then
circulated through a stainless steel sintered metal filter element
having a nominal pore size of 7 microns. Recirculation of the
emulsion was continued for 8 minutes. The emulsion was then added
with stirring to 350 ml deionized water maintained at 30 C and
containing 1.0 ml of 25% gluteraldehyde. During the addition, the
pH of the bath was monitored to insure that it remained between 7
and 8. Final pH was 7.0. Low shear mixing was continued for
approximately 21/2 hours until the isopropyl acetate had completely
volatilized. Polyoxamer 188 in the amount of 0.75 gm was then
dissolved into the bath. The resulting microspheres were retrieved
by centrifugation and washed 2 times in an aqueous solution of
0.25% polyoxamer.
[0067] Microscopic inspection revealed hollow spherical polymer
microparticles having an outer protein layer and an inner organic
liquid core. The suspension was formulated with a glycine/PEG 3350
excipient solution, then lyophilized. The resulting dry cake was
reconstituted with deionized water and examined under the
microscope to reveal that the microparticles were spherical,
discrete, and contained a gaseous core.
EXAMPLE 12
[0068] PEG Modification of the Microparticle Surface
[0069] Microparticles were prepared in a manner similar to example
9. After centrifugation, 4 ml of the microparticles containing
cream (approximately 11 ml total yield) was resuspended in 31 ml
deionized water. To this was added a 10 ml solution containing 0.3
gm methoxy-peg-NCO 5000 and the pH was adjusted to 8.7. The mixture
was allowed to react at room temperature with mild agitation for 4%
hours. At the end of this period the pH was measured to be 7.9. The
microparticles were retrieved by centrifugation and washed 2 times
in a 0.25% solution of polyoxamer 188. The suspension was
formulated with a glycine/PEG 3350 excipient solution, then
lyophilized. The resulting dry cake was reconstituted with
deionized water and examined under the microscope to reveal that
the microparticles were spherical, discrete, and contained a
gaseous core.
EXAMPLE 13
[0070] Post-fabrication, Modification of Size Distribution
[0071] A quantity of microparticles were first prepared in a manner
similar to example 1 with procedures modified to provide a
broadened size spectrum. After washing and retrieval by
centrifugation roughly half the microparticle containing cream was
diluted to 125 ml with a 0.25% solution of polyoxamer 188. The
suspension was then filtered using a 5 micron sieve type pc
membrane filter (Nuclepore) housed in a stirred cell (Amicon). The
retentate was discarded while the permeate was again filtered using
a 3 micron sieve type filter in the stirred cell system until the
retentate volume reached approximately 20 ml. The retentate was
diluted to a volume of 220 ml using 0.25% polyoxamer 188 solution.
The 3 micron filtration process was repeated until the retentate
volume was again approximately 20 ml.
[0072] FIG. 3 provides a comparison of the volumetric size
distribution of the unfiltered microparticle suspension with the 5
micron permeate and the 3 micron retentate. The results, derived
from a Malvern Micro particle size analyzer show a stepwise
narrowing of the size spectrum toward a specific size range defined
by the pore size of the filters used.
EXAMPLE 14
[0073] Representative Canine Study of Echogenicity
[0074] A 31 kg, thoracotomized male mongrel dog was injected with 1
cc of reconstituted microparticle composition made according to
example 4. This was delivered to the circulation through a
peripheral venous injection. Triggered harmonic ultrasound imaging
(once every beat) of the left ventricle was performed for 9
minutes. A contrast effect could be seen in the myocardium during
triggered imaging. Real-time (30 Hz) harmonic ultrasound imaging
over the next 4 minutes increased bubble destruction. Left
ventricular opacification remained persistent over the 13 minute
imaging period. No adverse hemodynamic effects were observed.
[0075] In a separate study, 0.1 cc of reconstituted microparticle
agent was administered similarly to a thoracotomized male mongrel
dog. Triggered harmonic ultrasound imaging was performed for 1
minute, followed by 4 minutes of increased microparticle
destruction with real-time imaging. Again, no adverse hemodynamics
effects were seen, and left ventricular opacification was apparent
and persistent.
EXAMPLE 15
[0076] Dye Loading of Albumin Polylactide Microparticles
[0077] A lyophilized cake in a 10 ml serum vial, composed of
excipient and lactide-containing microparticles prepared in a
manner similar to Example 11 was placed into a 50 ml centrifuge
tube. Enough isopropyl alcohol was added to cover the cake and it
was allowed to soak for 30 seconds. Aqueous Pluronic F68 solution
(0.25% w/w) was added to fill the tube. After centrifuging, the
supernatant was removed and another rinse performed. A saturated,
filtered solution of rhodamine B was added to the microparticles
and allowed to soak overnight. Under the microscope, the
microparticles appeared filled with dye solution. A dye saturated
F68 solution was made to use as a lyophilization excipient. Four ml
of the excipient was combined with the approximately 2 ml of
microcapsule containing solution and the resulting mixture was
split between two 10 ml serum vials. The vials were frozen at -80 C
and lyophilized in a FTS tray dryer. Both vials were purged with
perfluorobutane gas by five pump-down purge cycles with a vacuum
pump. Observation showed some microparticles that were half full of
red solution and half full of gas. There was no obvious leakage of
the dye from these microparticles during observation. The
microparticles were rinsed with four, 20 ml portions of F68
solution on a vacuum filter. The microparticles were placed in a
cuvette, centrifuged, and an initial spectra was taken. The cuvette
was sonicated in an ultrasonic bath, centrifuged, and another
spectra taken.
1 Abs. Initial (553-800) Abs. Sonicated (553-800) 1.164 1.86
[0078] The higher absorption after sonication indicates that
encapsulated dye was released upon insonation of the
microparticles.
EXAMPLE 16
[0079] Preparation of Wall Modified Albumin Polycaprolactone
Microparticles
[0080] Albumin coated microcapsules were prepared in a manner
similar to example 9 with the exception that 0.20 gm paraffin was
also dissolved into the organic solution along with the
polycaprolactone and the cyclooctane.
[0081] Microscopic inspection of the finished microparticle
suspension revealed spherical particles having a morphology and
appearance virtually identical to those prepared without the
addition of paraffin.
EXAMPLE 17
[0082] Dye Loading of Human Serum Albumin Polycaprolactone
Microparticles
[0083] A lyophilized cake in, a 10 ml serum vial, composed of
excipient and paraffin-containing microparticles prepared in
accordance with example 16 was placed into a 50 ml centrifuge tube.
The cake was covered with methanol and allowed to soak for 30
seconds. The tube was then filled with an aqueous solution of 0.25%
(w/w) Pluronic F68, gently mixed, and centrifuged in order to
precipitate the now fluid-filled microcapsules. The supernatant was
removed and the tubes were again filled with pluronic solution. The
microparticles were resuspended by vortexing and again centrifuged.
After removing the supernatant solution, two ml of a saturated,
filtered solution of brilliant blue G dye in 0.25% (w/w) aqueous
F68 was added. The microparticles were allowed to soak for
approximately 72 hours. Microscopic examination revealed 90-95% of
the microparticles to be filled with dye solution. A lyophilization
excipient was prepared. Four ml of the excipient was added to the
microparticle solution and mixed by vortexing. Two 10 ml serum
vials were filled with 3 ml each of solution and frozen at
-80.degree. C. The vials were lyophilized on a FTS flask
lyophilizer. Both vials and a portion of deionized water were
purged with perfluorobutane for 10 minutes. Both vials were
reconstituted with deionized water and rinsed with two 40 ml
portions of 0.25% (w/w) F68 solution on a vacuum filter. The
resulting microparticle solution was split into two 3 ml portions.
One portion was sonicated in an ultrasonic bath to rupture the
bubbles. Both portions were diluted 1/10 with F68 solution and
placed into UV-visible cuvettes. The cuvettes were centrifuged and
a visible spectra was taken.
2 Absorption (at 605 nm-800 nm) Sonicated 0.193 Non-sonicated
0.136
[0084] The higher absorption after sonication indicates that
encapsulated dye was released upon insonation of the
microcapsules.
EXAMPLE 18
[0085] Acoustic Resonance of Microparticles
[0086] To demonstrate a method of acoustically tuning the
microparticle construct, microparticles prepared in accordance with
the procedures described in examples 9 and 16 were reconstituted
with deionized water and compared for their acoustic properties
using procedures described as follows:
[0087] Two matched 5 MHz transducers were placed in a tank filled
with degassed water facing one another. Water depth was
approximately 3 inches. The transducers, one an emitter and the
other a receiver, were positioned 6 inches apart to maximize the
received signals. A 2 inch diameter, 2 cm wide circular chamber was
placed between the two transducers with the mid chamber position at
3 inches from the emitter. The two circular faces of the chamber
were covered with 3 mil polyethylene film and the chamber was then
filled with degassed water. Sound waves readily propagated from the
emitter through the chamber to the receiver. The sound source was
set to Gaussian Noise with 10 Volt peak to peak amplitude output
from the ultrasound generator. The receiver signal is amplified
with a 17 dB preamp and an oscilloscope. The oscilloscope digital
electronics can perform Fast Fourier Transforms (FFT) of the
received wave forms and display these distributions. After baseline
readings were made, test microparticle contrast materials were
delivered within the chamber via hypodermic syringe and thoroughly
mixed therein by pumping the syringe. During post-test evaluation,
the FFT data was converted into the Transfer Function of the test
agent.
[0088] The Transfer Function (TF) is determined by dividing the
bubble transmission spectral data by the spectral data without
bubbles, i.e:
TF=T(f).sub.with bubbles/T(f).sub.no bubbles
[0089] where T(f) is requested by the FFT.
[0090] The contrast agent selectively attenuates sound waves
depending upon its spectral distribution, i.e. more sound energy is
absorbed at or near bubble resonance than off-resonance. Thus the
procedure can be used to assess the resonant spectral distribution
of the agent.
[0091] Data derived from the two agents with nearly identical size
distribution but different inner shell thickness were collected on
the same day with the same equipment set at the same settings.
Everything else was held constant for a variety of agent
dosages.
[0092] Normalization of the spectra was performed by dividing the
spectral array by the minimal value. Thus the peak value becomes
unity and when plotted on the same graph it becomes quite easy to
differentiate the two graphs. These normalized data are presented
in FIG. 4.
[0093] Inspection of the results shown in FIG. 4 clearly show that
when shell wall compliance is increased, the resonant frequency can
be made to shift from 2.3 MHz to 8.9 MHz. Thus, the resonant
frequency of an agent can be controlled by controlling the wall
composition and thickness.
EXAMPLE 19
[0094] Effect of Acoustic Properties on In-Vivo Echogenicity
[0095] Two air-containing microparticle formulations were evaluated
for efficacy in-vivo. One vial of lyophilized microparticles was
prepared as described in Examples 1 and 2 (formulation A). A second
vial of lyophilized microparticles were prepared in a manner
similar to that described in Examples 1 and 2 except that four
times the amount of polymer was used, yielding microcapsules with a
thick inner wall and hence a higher resonant frequency (formulation
B). Both vials were reconstituted immediately prior to use. From
particle size analysis, both formulations had a mean microparticle
diameter of approximately 4 microns and nearly identical
microparticle concentration. In-vitro acoustical characterization
showed formulation A to have a resonant frequency near 5 MHz, and
formulation B to have a resonant frequency greater than 10 MHz. A 5
MHz transesophageal ultrasound probe was positioned in the
esophagus of an anesthetized dog such that a four-chamber view of
the heart was obtained. The reconstituted microparticle suspension
(4 cc of formulation A) was injected into the femoral vein of the
dog. The appearance of the contrast agent was clearly noted in the
ultrasound image of the right and left chambers of the heart.
Subsequently, 4 cc of the thick walled microparticle suspension
(formulation B) was injected into the femoral vein of the dog.
While the appearance of the contrast agent was again clearly noted
in the ultrasound image of the heart, the contrast effect was
substantially diminished when compared to the equivalent volume
injection of formulation A. Subsequent injections of dilutions made
from formulation A demonstrated a greater than four fold dose
effectiveness of formulation A which had a resonant frequency near
the center frequency of the ultrasound diagnostic system as
compared to formulation B with a greater peak resonant
frequency.
* * * * *